Does the media prefer OGN or SGP?

In the previous week, Spyglass Pharma had 1 more articles in the media than Organon & Co.. MarketBeat recorded 3 mentions for Spyglass Pharma and 2 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.51 beat Spyglass Pharma's score of 0.46 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyglass Pharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SGP or TARS?

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Spyglass Pharma. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 3 mentions for Spyglass Pharma. Tarsus Pharmaceuticals' average media sentiment score of 0.92 beat Spyglass Pharma's score of 0.46 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARQT or SGP?

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Spyglass Pharma. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 3 mentions for Spyglass Pharma. Arcutis Biotherapeutics' average media sentiment score of 0.46 beat Spyglass Pharma's score of 0.46 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, SGP or MBX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A MBX Biosciences N/A N/A -$86.97M -$2.41 N/A

Is SGP or MBX more profitable?

MBX Biosciences' return on equity of -26.02% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Spyglass Pharma N/A -62.40% -24.83% MBX Biosciences N/A -26.02% -24.94%

Does the media prefer SGP or MBX?

In the previous week, Spyglass Pharma and Spyglass Pharma both had 3 articles in the media. Spyglass Pharma's average media sentiment score of 0.46 beat MBX Biosciences' score of 0.45 indicating that Spyglass Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MOR or SGP?

Spyglass Pharma has a consensus price target of $44.00, suggesting a potential upside of 51.31%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Spyglass Pharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is MOR or SGP more profitable?

Spyglass Pharma has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Spyglass Pharma's return on equity of -62.40% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Spyglass Pharma N/A -62.40% -24.83%

Spyglass Pharma (SGP) Competitors

$29.08 -0.25 (-0.85%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$29.02 -0.05 (-0.19%)

As of 09/18/2026 07:30 PM Eastern

Compare

SGP vs. OGN, TARS, ARQT, MBX, and MOR

Should you buy Spyglass Pharma stock or one of its competitors? Spyglass Pharma's main competitors and comparable companies include Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), Arcutis Biotherapeutics (ARQT), MBX Biosciences (MBX), and MorphoSys (MOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Spyglass Pharma compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Spyglass Pharma had 1 more articles in the media than Organon & Co.. MarketBeat recorded 3 mentions for Spyglass Pharma and 2 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.51 beat Spyglass Pharma's score of 0.46 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyglass Pharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organon & Co. has a net margin of 3.41% compared to Spyglass Pharma's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Spyglass Pharma	N/A	-62.40%	-24.83%

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Organon & Co. presently has a consensus price target of $11.40, indicating a potential downside of 16.70%. Spyglass Pharma has a consensus price target of $44.00, indicating a potential upside of 51.31%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Organon & Co. has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.77
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Summary

Organon & Co. beats Spyglass Pharma on 10 of the 14 factors compared between the two stocks.

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Spyglass Pharma (NASDAQ:SGP) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Spyglass Pharma has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Tarsus Pharmaceuticals	$451.36M	7.59	-$66.42M	-$1.09	N/A

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Spyglass Pharma. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 3 mentions for Spyglass Pharma. Tarsus Pharmaceuticals' average media sentiment score of 0.92 beat Spyglass Pharma's score of 0.46 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyglass Pharma currently has a consensus target price of $44.00, suggesting a potential upside of 51.31%. Tarsus Pharmaceuticals has a consensus target price of $94.00, suggesting a potential upside of 20.37%. Given Spyglass Pharma's higher possible upside, equities analysts clearly believe Spyglass Pharma is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spyglass Pharma has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

Summary

Tarsus Pharmaceuticals beats Spyglass Pharma on 10 of the 15 factors compared between the two stocks.

How does Spyglass Pharma compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Arcutis Biotherapeutics presently has a consensus price target of $35.57, indicating a potential upside of 40.35%. Spyglass Pharma has a consensus price target of $44.00, indicating a potential upside of 51.31%. Given Spyglass Pharma's higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Arcutis Biotherapeutics has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.47	-$16.14M	$0.21	120.69
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Spyglass Pharma. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 3 mentions for Spyglass Pharma. Arcutis Biotherapeutics' average media sentiment score of 0.46 beat Spyglass Pharma's score of 0.46 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has a net margin of 6.15% compared to Spyglass Pharma's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Spyglass Pharma	N/A	-62.40%	-24.83%

Summary

Arcutis Biotherapeutics beats Spyglass Pharma on 10 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to MBX Biosciences?

Spyglass Pharma (NASDAQ:SGP) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

MBX Biosciences is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

In the previous week, Spyglass Pharma and Spyglass Pharma both had 3 articles in the media. Spyglass Pharma's average media sentiment score of 0.46 beat MBX Biosciences' score of 0.45 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MBX Biosciences' return on equity of -26.02% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
MBX Biosciences	N/A	-26.02%	-24.94%

Spyglass Pharma currently has a consensus target price of $44.00, suggesting a potential upside of 51.31%. MBX Biosciences has a consensus target price of $77.00, suggesting a potential upside of 22.40%. Given Spyglass Pharma's higher possible upside, research analysts plainly believe Spyglass Pharma is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Spyglass Pharma and MBX Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

How does Spyglass Pharma compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Spyglass Pharma had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Spyglass Pharma and 0 mentions for MorphoSys. Spyglass Pharma's average media sentiment score of 0.46 beat MorphoSys' score of 0.00 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Spyglass Pharma	Neutral

Spyglass Pharma has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Spyglass Pharma's return on equity of -62.40% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Spyglass Pharma	N/A	-62.40%	-24.83%

Spyglass Pharma has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Spyglass Pharma has a consensus price target of $44.00, suggesting a potential upside of 51.31%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Spyglass Pharma beats MorphoSys on 9 of the 14 factors compared between the two stocks.

Get Spyglass Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGP vs. The Competition

Export

Metric	Spyglass Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$972.23M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-4.15	653.41	214.59	20.89
Price / Sales	N/A	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	N/A	10.53	10.46	6.33
Net Income	-$39.87M	$2.82B	$3.49B	$358.33M
7 Day Performance	5.67%	1.69%	0.59%	1.12%
1 Month Performance	6.79%	0.83%	-2.01%	-2.67%
1 Year Performance	N/A	3.90%	18.09%	6.01%

Spyglass Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGP Spyglass Pharma	2.4973 of 5 stars	$29.08 -0.9%	$44.00 +51.3%	N/A	$972.23M	N/A	N/A	65	News Coverage Analyst Upgrade High Trading Volume
OGN Organon & Co.	1.2561 of 5 stars	$13.68 +0.2%	$11.40 -16.6%	+26.0%	$3.59B	$6.13B	17.76	10,000	Positive News
TARS Tarsus Pharmaceuticals	2.9285 of 5 stars	$78.13 -2.3%	$92.57 +18.5%	+44.5%	$3.42B	$606.33M	N/A	50	Analyst Upgrade Insider Trade
ARQT Arcutis Biotherapeutics	3.626 of 5 stars	$23.45 -3.4%	$35.57 +51.7%	+43.1%	$2.94B	$463.98M	111.38	354	News Coverage
MBX MBX Biosciences	2.6118 of 5 stars	$60.50 +1.7%	$77.00 +27.3%	+524.7%	$2.91B	N/A	N/A	63

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGP) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyglass Pharma (SGP) Competitors

SGP vs. OGN, TARS, ARQT, MBX, and MOR

How does Spyglass Pharma compare to Organon & Co.?

Summary

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Summary

How does Spyglass Pharma compare to Arcutis Biotherapeutics?

Summary

How does Spyglass Pharma compare to MBX Biosciences?

Summary

How does Spyglass Pharma compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyglass Pharma (SGP) Competitors

SGP vs. OGN, TARS, ARQT, MBX, and MOR

How does Spyglass Pharma compare to Organon & Co.?

Does the media prefer OGN or SGP?

Is OGN or SGP more profitable?

Do institutionals and insiders have more ownership in OGN or SGP?

Do analysts rate OGN or SGP?

Which has better valuation and earnings, OGN or SGP?

Summary

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Which has preferable earnings and valuation, SGP or TARS?

Does the media prefer SGP or TARS?

Do analysts recommend SGP or TARS?

Do institutionals & insiders have more ownership in SGP or TARS?

Is SGP or TARS more profitable?

Summary

How does Spyglass Pharma compare to Arcutis Biotherapeutics?

Do analysts rate ARQT or SGP?

Which has preferable valuation & earnings, ARQT or SGP?

Does the media prefer ARQT or SGP?

Is ARQT or SGP more profitable?

Summary

How does Spyglass Pharma compare to MBX Biosciences?

Which has better earnings & valuation, SGP or MBX?

Does the media prefer SGP or MBX?

Is SGP or MBX more profitable?

Do analysts prefer SGP or MBX?

Summary

How does Spyglass Pharma compare to MorphoSys?

Does the media prefer MOR or SGP?

Is MOR or SGP more profitable?

Which has stronger earnings and valuation, MOR or SGP?

Do analysts prefer MOR or SGP?

Do institutionals & insiders hold more shares of MOR or SGP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools